Alumis Inc Cash Flow Conversion Efficiency
Alumis Inc cash flow conversion efficiency. Based on the latest financial reports, Alumis Inc (ALMS) has a cash flow conversion efficiency ratio of -0.180x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.50 Million) by net assets ($452.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alumis Inc (2022–2025)
Cash flow conversion efficiency of Alumis Inc from 2022 to 2025. This chart illustrates how Alumis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alumis Inc share price for real-time trading data and today's change.
Alumis Inc Cash Flow Conversion Ratio Explained
Alumis Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alumis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alumis Inc ranked by their cash flow conversion efficiency. Also see market cap of Alumis Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morguard Corporation
TO:MRC
|
0.007x |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
0.160x |
|
Cosmoam&T
KO:005070
|
-0.065x |
|
SP Group A/S
CO:SPG
|
0.069x |
|
TrustCo Bank Corp NY
NASDAQ:TRST
|
0.018x |
|
Fujian Guanfu Modern Household Wares Co Ltd
SHE:002102
|
-0.039x |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
0.050x |
|
Lontium Semiconductor Corp. A
SHG:688486
|
N/A |
Annual Cash Flow Conversion Efficiency for Alumis Inc (2022–2025)
The table below shows the annual cash flow conversion efficiency of Alumis Inc from 2022 to 2025. Review Alumis Inc (ALMS) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $301.30 Million | $-369.52 Million | -1.226x | -25.06% |
| 2024-12-31 | $260.10 Million | $-255.08 Million | -0.981x | -355.98% |
| 2023-12-31 | $-339.26 Million | $-129.97 Million | 0.383x | -30.56% |
| 2022-12-31 | $-195.24 Million | $-107.72 Million | 0.552x | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more